Evaluating Venetoclax for Waldenström Macroglobulinemia in Real Life
Patients Treated in Real Life With VEnetoclax for WAldenström Macroglobulinemia
Poitiers University Hospital · NCT06200220
This study is testing how well Venetoclax works and how safe it is for people with Waldenström macroglobulinemia in everyday treatment situations.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 45 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Poitiers University Hospital (other) |
| Locations | 1 site (Poitiers) |
| Trial ID | NCT06200220 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the effectiveness and safety of Venetoclax in patients with Waldenström macroglobulinemia who have received treatment in real-world settings. It focuses on gathering retrospective data from multiple centers to understand how Venetoclax performs outside of controlled clinical trial environments. The study will analyze patient responses and tolerance to the treatment, contributing valuable insights into its real-life application.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with Waldenström macroglobulinemia who have been treated with Venetoclax.
Not a fit: Patients who have not been treated with Venetoclax or do not have a diagnosis of Waldenström macroglobulinemia may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide crucial real-world evidence supporting the use of Venetoclax for treating Waldenström macroglobulinemia, potentially improving patient outcomes.
How similar studies have performed: While there have been successful trials with Venetoclax in other conditions, this study is novel as it focuses on real-world data for Waldenström macroglobulinemia.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Waldenstrom's macroglobulinemia * Treatment with Venetoclax * Non opposition Exclusion Criteria: none
Where this trial is running
Poitiers
- CHU Poitiers — Poitiers, France (RECRUITING)
Study contacts
- Study coordinator: cécile tomowiak, Dr
- Email: cecile.tomowiak@chu-poitiers.fr
- Phone: +33 (0)5.49.44.43.07
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Waldenstrom's Macroglobulinaemia Refractory